Bristol-Myers Squibb Company
NYSE: BMY
$58.73
-$0.14 (-0.2%)
Closing Price on November 25, 2024
BMY Articles
Tuesday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Costco Wholesale, Dollar General, Exxon Mobil, FedEx, Horizon Therapeutics, Hyatt Hotels, Lucid, Medtronic, Micron...
Published:
Wednesday's additional top analyst upgrades and downgrades were on Block, Bristol-Myers Squibb, Clorox, CSX, Kimberly-Clark, Merck, Match, Target and more.
Published:
The bear market rally that started in June is over and it is clearly a time to move to safer dividend stocks. These eight outstanding health care stocks make sense for worried investors now as they...
Published:
Monday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Cheniere Energy, Chewy, Costco Wholesale, CrowdStrike, Exact Sciences, Lululemon Athletica, New York Community Bancorp,...
Published:
Here are previews of three pharmaceutical giants set to report earnings before markets open on Friday.
Published:
Wednesday’s additional top analyst upgrades and downgrades included AbbVie, Bristol-Myers, JetBlue, and more.
Published:
A recent survey of global fund managers found that many have turned to health care for some stability in these uncertain times. These eight high-dividend-paying stocks are rated Buy at top Wall...
Published:
Monday's top analyst upgrades and downgrades included Adobe, Arista Networks, AT&T, Bristol-Myers Squibb, Canopy Growth, Deere, Eli Lilly, Invesco, Medtronic, Mosaic, 3M, Roblox, Starbucks, Tesla,...
Published:
Friday’s top analyst upgrades and downgrades included Altice USA, AppLovin, Biogen, Bristol-Myers Squibb, Broadcom, Ciena, Cloudflare, Denison Mines, Diageo, Eli Lilly, Rio Tinto and Southwest...
Published:
With the potential for far lower returns in the coming year, total return becomes a key ingredient for investment success. These five top health care stocks look like very solid ideas for 2022, as...
Published:
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
Published:
Monday afternoon's analyst upgrades and downgrades included Bristol-Myers Squibb, Intel, Merck, Newell Brands, Snap, Spotify Technology and Tilray.
Published:
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
Published:
These four big pharmaceutical stocks are rated Buy by top Wall Street firms and look like very good ideas for investors, especially now that the market is overbought and the slow seasonal market...
Published:
These six top Goldman Sachs stock picks all pay healthy dividends and offer great total return potential and less potential volatility in a very overbought stock market that may be poised for a...
Published: